Efor news & technical articles
14/11/2023
Efor accelerates the structuring of its center of excellence for health data valorization.
With a position among the leaders in specialized consulting for Life Sciences industries, the Efor Group supports its clients thro
6/11/2023
ICH Q12 application for the implementation of a change: example of a site transfer
The ICH Q12 guideline entitled « Technical and regulatory considerations for pharmaceutical product life cycle management” is
24/10/2023
Efor X Institut Pasteur de Dakar
We are delighted to announce that Efor has entered into a collaboration with the Institut Pasteur de Dakar to support its major ex
19/10/2023
Committed to Pink October! 🎗️
At Efor, we are proud to commit ourselves to a cause that is particularly close to our hearts: raising awareness for breast cancer
17/10/2023
Proud to have run for cancer research!!
A group of our Eforcenes took part in the charity run organized by the Leon BERARD center this Sunday.
Join our team
Consult our offers
9/10/2023
Clinical evaluation according to Article 61(10) of Medical Device Regulation (EU) 2017/745
Purpose of conducting a clinical evaluationRegulation (EU) 2017/745 (article 2(44)) relating to medical devices defines clinical e
25/09/2023
Toxicological risk assessment and 2023 revision of ISO 10993-17 standard
All the answers about ISO 10993-17 and its revision
21/09/2023
Relocation of our Norman Agency
After Grenoble, it's now the turn of our Norman agency located in Val de Reuil to change environment and move into their new premi
Got a question?
Contact our experts
23/08/2023
Animal testing and medical devices: where do we stand?
Animals have long been used in the research phase to guarantee the safety & efficacy of pharma and DM products. What about today?
24/07/2023
Machine Learning applied to OMICS data
Machine Learning is widely used in data science, but did you know that it can also be applied to OMICS data?
24/07/2023
Efor ranked as essential in regulatory affairs in Décideurs Magazine
📣We are pride to announce that the Efor Group is now ranked “Leading” in the field of regulatory affairs consu
